background
umbil
cord
blood
transplant
ucbt
use
patient
match
donor
engraft
often
take
longer
standard
allogen
transplant
like
increas
risk
infect
character
specif
infect
outcom
adult
undergo
ucbt
center
method
adult
underw
ucbt
januari
decemb
includ
infecti
episod
month
year
ucbt
review
result
fiftyseven
patient
underw
ucbt
neutrophil
engraft
total
infecti
episod
occur
patient
within
day
postucbt
virus
caus
infect
cytomegaloviru
caus
infecti
episod
common
day
human
herpesviru
occur
episod
common
within
day
caus
death
bacteria
respons
infect
commonli
bacteremia
due
staphylococcu
spp
enterococcu
spp
enterobacteriacea
invas
fungal
infect
aspergillosi
fatal
overal
mortal
first
year
thirteen
death
infect
occur
first
day
first
day
postucbt
patient
never
engraft
die
infect
within
day
postucbt
conclus
infecti
complic
common
ucbt
especi
first
day
death
viral
infect
fewer
expect
delay
engraft
nonengraft
continu
convey
increas
risk
fatal
bacteri
fungal
infect
postucbt
umbil
cord
blood
ucb
cell
suitabl
sourc
stem
cell
patient
requir
hematopoiet
cell
transplant
hct
match
donor
use
ucb
cell
mostli
studi
children
hematolog
malign
extend
adult
popul
pauciti
relat
match
donor
advantag
use
ucb
cell
hct
includ
abil
use
human
leukocyt
antigen
hla
mismatch
cell
without
signific
advers
effect
graft
function
decreas
incid
graftversushost
diseas
gvhd
transplant
howev
decreas
quantiti
cell
avail
transplant
immunolog
immatur
ucb
cell
link
delay
engraft
ucb
transplant
ucbt
prolong
neutropenia
well
recogn
risk
factor
sever
infect
patient
receiv
ucbt
appear
increas
risk
compar
allogen
hct
recipi
perhap
due
delay
engraft
infect
estim
caus
nonrelaps
mortal
patient
ucbt
compar
allogen
hct
viral
infect
especi
cytomegaloviru
cmv
human
herpesviru
hhv
associ
increas
morbid
mortal
postucbt
sought
character
infecti
complic
outcom
patient
receiv
ucbt
institut
period
retrospect
studi
conduct
univers
michigan
health
system
ann
arbor
mi
karmano
cancer
center
detroit
mi
approv
grant
institut
review
board
center
adult
patient
year
age
underw
ucbt
studi
center
januari
decemb
includ
studi
medic
record
review
identifi
infecti
complic
month
ucbt
year
transplant
demograph
inform
underli
hematolog
diseas
condit
regimen
prophylaxi
time
engraft
episod
infect
treatment
outcom
collect
patient
experienc
relaps
underli
malign
ucbt
exclud
analysi
date
relaps
document
studi
data
collect
manag
use
redcap
electron
data
captur
tool
infecti
episod
defin
episod
fever
hemodynam
instabl
antimicrobi
therapi
initi
separ
least
hour
previou
episod
day
episod
count
first
day
antimicrobi
administr
time
neutrophil
engraft
ucbt
defin
first
consecut
day
absolut
neutrophil
count
graftversushost
diseas
venoocclus
diseas
complic
relat
transplant
includ
infect
defin
accord
nccn
guidelin
condit
regimen
classifi
either
myeloabl
reducedintens
use
criteria
propos
bacigalupo
et
al
nation
institut
allergi
infecti
diseas
mycos
studi
group
criteria
use
definit
invas
fungal
infect
cytomegaloviru
infect
endorgan
diseas
defin
current
consensu
definit
routin
screen
cmv
viremia
perform
molecular
test
cmv
epsteinbarr
viru
perform
febril
episod
patient
receiv
antibacteri
prophylaxi
typic
fluoroquinolon
start
day
transplant
continu
engraft
antibacteri
prophylaxi
restart
subsequ
neutropenia
gvhd
antifung
prophylaxi
initi
day
posttranspl
continu
engraft
viral
prophylaxi
acyclovir
start
day
transplant
continu
least
year
routin
prophylaxi
cmv
given
pneumocysti
prophylaxi
either
pentamidin
trimethoprimsulfamethoxazol
start
day
provid
neutrophil
engraft
occur
conduct
descript
data
analys
variabl
student
test
fisher
exact
test
oneway
analysi
varianc
use
determin
differ
group
statist
analys
complet
use
spss
softwar
version
spss
inc
chicago
il
adult
patient
underw
ucbt
januari
decemb
mean
age
year
women
thirtynin
patient
receiv
ucbt
myelodysplast
syndrom
acut
myeloid
leukemia
lymphoid
malign
anoth
hematolog
malign
tabl
ten
patient
prior
autolog
hct
patient
prior
ucbt
differ
institut
twentythre
patient
infect
preced
month
ucbt
tabl
bacteremia
clostridium
difficil
infect
common
document
infect
ucbt
twentyseven
patient
least
episod
febril
neutropenia
month
transplant
thirtyeight
patient
cmv
antibodi
posit
transplant
condit
myeloabl
patient
reducedintens
tabl
doubleunit
ucbt
receiv
patient
singleunit
ucbt
receiv
patient
patient
number
unit
receiv
record
median
ucb
cell
volum
infus
cell
rang
cell
median
nucleat
cell
per
kilogram
bodi
weight
fortyeight
patient
hla
mismatch
fiftysix
patient
antibacteri
prophylaxi
time
ucbt
consist
fluoroquinolon
tabl
ten
patient
receiv
receiv
clindamycin
three
patient
given
secondari
prophylaxi
infect
occur
transplant
patient
receiv
antivir
prophylaxi
acyclovir
mg
twice
daili
antifung
prophylaxi
consist
azol
echinocandin
tabl
fortyseven
patient
receiv
pneumocysti
prophylaxi
engraft
remain
patient
neutrophil
engraft
patient
receiv
gvhd
prophylaxi
tacrolimu
mycophenol
mofetil
n
cyclosporinemycophenol
mofetil
n
tacrolimu
alon
n
sirolimusmycophenol
mofetil
n
patient
develop
profound
neutropenia
thrombocytopenia
postucbt
fortyseven
patient
neutrophil
engraft
mean
day
patient
never
achiev
engraft
die
within
day
ucbt
lost
follow
day
platelet
engraft
occur
patient
mean
time
day
time
engraft
differ
patient
receiv
singl
versu
doubl
ucbt
graftversushost
diseas
occur
patient
twentyseven
acut
gvhd
skin
involv
gastrointestin
involv
chronic
gvhd
skin
involv
gastrointestin
involv
addit
patient
acut
follow
chronic
gvhd
mean
time
develop
acut
gvhd
day
chronic
gvhd
day
total
episod
infect
report
patient
median
number
episod
per
patient
rang
greatest
number
infect
occur
within
day
postucbt
episod
patient
among
earli
infect
occur
neutrophil
engraft
although
fewer
number
infect
continu
occur
throughout
followup
period
postucbt
episod
day
episod
day
viral
infect
common
follow
bacteri
fungal
infect
episod
infect
protozo
helminth
pathogen
sever
differ
infect
present
concurr
infecti
episod
irrespect
time
posttranspl
mean
number
infecti
episod
per
patient
rang
per
year
period
studi
eightyf
episod
viral
infect
identifi
patient
tabl
cytomegaloviru
common
viral
infect
onset
vari
postucbt
cytomegaloviru
infect
uncommon
earli
transplant
common
pathogen
found
day
postucbt
total
episod
cmv
note
patient
time
period
character
viremia
alon
involv
endorgan
diseas
includ
coliti
pneumonia
antivir
treatment
either
foscarnet
ganciclovir
administ
episod
episod
cmv
infect
occur
concurr
infect
commonli
coinfect
vancomycinresist
enterococcu
vre
occur
episod
patient
develop
cmv
infect
antibodi
cmv
ucbt
remain
seroposit
patient
includ
receiv
antithymocyt
globulin
atg
develop
cmv
infect
human
engraft
differ
significantli
patient
viremia
without
viremia
viral
infect
seen
less
commonli
cmv
bk
viru
infect
note
episod
character
viruria
hemorrhag
cystiti
patient
acyclovir
prophylaxi
hsv
infecti
episod
involv
hsv
reactiv
sever
patient
meningoenceph
widespread
dissemin
viru
becam
increasingli
resist
acyclovir
foscarnet
viral
infect
involv
respiratori
tract
occur
day
postucbt
coronaviru
infect
sever
total
episod
bacteri
infect
report
patient
tabl
common
bacteri
infect
ucbt
bloodstream
infect
bsi
occur
episod
patient
central
lineassoci
bsi
clabsi
account
bsi
predomin
organ
coagulaseneg
staphylococcu
account
episod
clabsi
vancomycinresist
enterococcu
pathogen
bsi
episod
clabsi
gramneg
bacilli
account
anoth
bsi
episod
includ
clabsi
polymicrobi
bacteremia
note
occas
clostridium
difficil
infect
account
episod
patient
trend
vre
infect
c
difficil
infect
occur
often
first
day
posttranspl
time
occurr
significantli
differ
bacteri
pathogen
bacteri
infect
note
tabl
three
patient
mycobacteri
infect
one
patient
immigr
malaysia
develop
fulmin
pulmonari
tuberculosi
day
ucbt
die
sever
week
later
two
patient
pneumonia
due
nontubercul
mycobacteria
patient
whose
cours
complic
bronchiol
obliteran
syndrom
develop
pulmonari
infect
mycobacterium
avium
year
ucbt
pulmonari
infect
mycobacterium
abscessu
month
later
anoth
patient
develop
pneumonia
day
ucbt
bronchoalveolar
lavag
cultur
yield
mycobacterium
chelona
death
eleven
episod
invas
fungal
infect
record
patient
ucbt
invas
aspergillosi
note
patient
one
patient
episod
candida
glabrata
fungemia
median
time
ucbt
diagnosi
aspergillosi
day
rang
day
episod
candidemia
occur
day
day
ucbt
aspergillosi
defin
proven
probabl
possibl
patient
pulmonari
infect
spread
central
nervou
system
isol
central
nervou
system
infect
patient
develop
invas
aspergillosi
receiv
fluconazol
antifung
prophylaxi
receiv
micafungin
initi
receiv
voriconazol
switch
micafungin
develop
infect
receiv
voriconazol
throughout
postucbt
period
patient
infect
ucbt
document
recurr
infect
first
day
postucbt
one
patient
recurr
c
difficil
infect
anoth
recurr
vre
urinari
tract
infect
two
patient
recurr
bsi
vre
escherichia
coli
one
streptococcu
spp
one
addit
patient
treat
possibl
invas
aspergillosi
set
pneumonia
month
ucbt
comput
tomographi
scan
demonstr
full
resolut
airspac
opac
transplant
later
develop
probabl
invas
aspergillosi
day
ucbt
micafungin
prophylaxi
overal
mortal
first
year
postucbt
patient
addit
patient
die
year
thirteen
death
attribut
infect
tabl
malign
relaps
occur
patient
death
relaps
occur
includ
patient
die
year
caus
death
complic
sever
refractori
gvhd
sinusoid
obstruct
syndrom
graft
failur
hemophagocyt
lymphohistiocytosi
median
time
ucbt
death
infect
day
rang
median
time
death
malign
relaps
day
rang
p
among
patient
never
achiev
neutrophil
engraft
die
within
day
ucbt
infect
day
postucbt
seven
infect
led
death
occur
first
day
postucbt
patient
die
develop
infect
day
postucbt
patient
die
day
ucbt
n
earli
infect
due
invas
fungi
p
vre
p
enterobacteriacea
p
compar
surviv
day
transplant
n
even
though
cmv
common
infect
postucbt
death
patient
limbic
enceph
attribut
virus
current
studi
describ
burden
infecti
complic
adult
patient
ucbt
prior
studi
demonstr
high
infect
risk
children
procedur
contradictori
studi
regard
risk
infect
adult
patient
ucbt
viral
infect
associ
excess
morbid
mortal
ucbt
cytomegaloviru
reactiv
particular
concern
posit
cmv
serostatu
recipi
use
atg
monoclon
tcell
antibodi
condit
known
risk
factor
cmv
reactiv
increas
mortal
ucbt
previou
studi
infect
ucbt
found
rate
cmv
reactiv
note
rate
higher
note
allogen
hct
use
atg
condit
ucbt
recipi
previous
associ
increas
risk
cmv
reactiv
studi
cmv
reactiv
associ
atg
use
patient
receiv
agent
cytomegaloviru
infect
contribut
death
patient
cohort
cohort
second
frequent
pathogen
observ
consist
prior
report
often
present
viremia
without
endorgan
diseas
occur
earli
ucbt
clinic
signific
asymptomat
viremia
remain
controversi
howev
reactiv
independ
associ
graft
failur
ucbt
find
signific
relationship
graft
failur
patient
onset
viremia
patient
treat
foscarnet
may
block
develop
endorgan
diseas
due
human
herpesviru
respons
death
patient
develop
limbic
enceph
day
ucbt
patient
previous
treat
foscarnet
episod
viremia
accompani
pneumon
receipt
ucbt
describ
previous
risk
factor
develop
limbic
enceph
condit
associ
high
plasma
viral
load
observ
patient
univers
prophylaxi
hsv
common
practic
ucbt
patient
studi
standarddos
acyclovir
despit
appropri
antivir
prophylaxi
observ
episod
hsv
reactiv
sever
led
patient
death
acyclovir
resist
confirm
patient
die
dissemin
infect
acyclovir
resist
appear
common
hct
particularli
set
tcell
deplet
may
relat
prolong
use
acyclovir
prophylaxi
none
patient
highdos
acyclovir
use
center
antivir
prophylaxi
hct
rais
question
whether
prophylaxi
strategi
might
prevent
fatal
herpesviru
infect
increas
emphasi
screen
reactiv
cmv
whenev
fever
occur
prompt
treatment
like
respons
decreas
mortal
viral
pathogen
death
due
bacteri
fungal
pathogen
remain
high
ucbt
six
infecti
death
patient
popul
due
bacteremia
invas
aspergillosi
occur
first
day
transplant
surprisingli
bacteri
infect
common
throughout
time
period
mani
like
relat
presenc
indwel
cathet
infect
enterobacteriacea
vre
within
first
day
ucbt
associ
increas
mortal
prolong
time
neutrophil
engraft
ucbt
increas
period
recipi
high
risk
lifethreaten
bacteri
infect
although
antibacteri
prophylaxi
standard
care
hct
increas
antimicrobi
resist
limit
efficaci
sever
exist
oral
prophylact
regimen
center
vre
becom
common
caus
bacteremia
allogen
hct
recipi
also
emerg
problem
among
ucbt
recipi
center
infect
mycobacteria
uncommon
among
hct
recipi
report
frequenc
nontubercul
mycobacteri
infect
sever
report
case
relat
infect
central
venou
cathet
structur
lung
chang
bronchiectasi
associ
bronchiol
obliteran
syndrom
like
predispos
patient
infect
nontubercul
mycobacteria
late
transplant
case
one
patient
pulmonari
tuberculosi
less
common
hct
estim
rate
although
one
report
japan
note
incid
among
ucbt
recipi
invas
mold
infect
major
caus
death
cohort
invas
candida
infect
rare
patient
episod
candidemia
widespread
use
azol
prophylaxi
allogen
hct
recipi
like
chang
epidemiolog
invas
fungal
infect
popul
patient
cohort
die
invas
aspergillosi
neutrophil
engraft
none
receiv
prophylaxi
moldact
azol
high
burden
diseas
earli
ucbt
underscor
need
aggress
surveil
fungal
infect
need
moldact
azol
prophylaxi
despit
prior
pediatr
studi
demonstr
decreas
risk
gvhd
ucbt
saw
high
rate
gvhd
cohort
patient
die
sequela
severerefractori
gvhd
observ
higher
rate
acut
gvhd
chronic
gvhd
popul
previous
describ
possibl
higher
rate
acut
gvhd
ucbt
associ
greater
hla
mismatch
howev
exact
mechan
remain
unclear
limit
studi
includ
retrospect
natur
rel
small
sampl
size
addit
time
span
studi
chang
practic
particularli
regard
prophylaxi
infect
monitor
protocol
like
impact
risk
outcom
infect
summari
implement
strategi
screen
infect
cmv
onset
fever
treat
promptli
evolv
time
chang
landscap
infecti
complic
ucbt
cytomegaloviru
common
ucbt
associ
increas
mortal
delay
neutrophil
engraft
increas
risk
bacteri
fungal
infect
earli
ucbt
associ
increas
mortal
multipl
concurr
infect
present
one
third
episod
diagnosi
one
infect
prohibit
test
possibl
infect
